Management of lung transplantation in the COVID-19 era-An international survey #MMPMID33084144
Coiffard B; Lepper PM; Prud'Homme E; Daviet F; Cassir N; Wilkens H; Hraiech S; Langer F; Thomas PA; Reynaud-Gaubert M; Bals R; Schafers HJ; Papazian L; Seiler F
Am J Transplant 2021[Apr]; 21 (4): 1586-1596 PMID33084144show ga
It is unknown if solid organ transplant recipients are at higher risk for severe COVID-19. The management of a lung transplantation (LTx) program and the therapeutic strategies to adapt the immunosuppressive regimen and antiviral measures is a major issue in the COVID-19 era, but little is known about worldwide practice. We sent out to 180 LTx centers worldwide in June 2020 a survey with 63 questions, both regarding the management of a LTx program in the COVID-19 era and the therapeutic strategies to treat COVID-19 LTx recipients. We received a total of 78 responses from 15 countries. Among participants, 81% declared a reduction of the activity and 47% restricted LTx for urgent cases only. Sixteen centers observed deaths on waiting listed patients and eight centers performed LTx for COVID-19 disease. In 62% of the centers, COVID-19 was diagnosed in LTx recipients, most of them not severe cases. The most common immunosuppressive management included a decreased dose or pausing of the cell cycle inhibitors. Remdesivir, hydroxychloroquine, and azithromycin were the most proposed antiviral strategies. Most of the centers have been affected by the COVID-19 pandemic and proposed an active therapeutic strategy to treat LTx recipients with COVID-19.
free
free
free
Am+J+Transplant 2021 ; 21 (4): 1586-1596
